Rigorous evaluation certifies the superior quality of health information exchange and the highest standards of privacy and security. ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ -- Secure Exchange...

̶ Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation ̶ ̶ Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster...

Quanta Services, Inc. (NYSE: PWR) announced today that company management will participate in the Wolfe Research Utilities, Midstream & Clean Energy Conference 2024. Duke Austin, Chief Executive...

Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters,...

On September 14, 2024, BioCity presented interim clinical results on the safety and efficacy of its first-in-class antibody-drug conjugate (ADC) BC3195 targeting CDH3 (P-Cadherin) in a Phase I...